We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-11.42%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$474M
(-62%)
Cap. Flow
-$416M
Cap. Flow
% of AUM
-145.73%
Top 10 Holdings %
Top 10 Hldgs %
76.36%
Holding
35
New
4
Increased
1
Reduced
14
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$12.8M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$8.97M |
| 3 |
Alkermes
ALKS
|
+$7.31M |
| 4 |
DexCom
DXCM
|
+$4.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Integer Holdings
ITGR
|
+$35.4M |
| 2 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$21.7M |
| 3 |
Becton Dickinson
BDX
|
+$19.3M |
| 4 |
Quest Diagnostics
DGX
|
+$19.1M |
| 5 |
Medtronic
MDT
|
+$18.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.64% |
| 2 | Technology | 7.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ELGX
1
DELISTED
Endologix Inc
ELGX
| $31.8M | 11.12% |
380,000
-67,500
| -15% | -$5.56M |
|
|
2
Quest Diagnostics
DGX
$25.7B
| $26.1M | 9.13% |
365,000
-285,000
| -44% | -$19.1M |
|
|
PDCO
3
DELISTED
Patterson Companies, Inc.
PDCO
| $25.6M | 8.96% |
550,000
-500,000
| -48% | -$21.7M |
|
|
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
| $25.5M | 8.92% |
1,700,000
-225,000
| -12% | -$3.77M |
|
|
MDRX
5
DELISTED
Veradigm Inc. Common Stock
MDRX
| $21.8M | 7.63% |
1,650,000
-200,000
| -11% | -$2.63M |
|
|
IMPR
6
DELISTED
IMPRIVATA, INC COM
IMPR
| $21.6M | 7.56% |
1,710,000
-36,000
| -2% | -$411K |
|
|
7
Medtronic
MDT
$109B
| $18.8M | 6.56% |
250,000
-250,000
| -50% | -$18.8M |
|
|
8
Alkermes
ALKS
$8.22B
| $16.6M | 5.8% |
485,000
+185,000
| +62% | +$7.31M |
|
|
SPNC
9
DELISTED
Spectranetics Corp
SPNC
| $16M | 5.59% |
1,100,000
-250,000
| -19% | -$3.46M |
|
|
LMNX
10
DELISTED
Luminex Corp
LMNX
| $14.6M | 5.09% |
750,000
-175,000
| -19% | -$3.33M |
|
11
Bio-Rad Laboratories Class A
BIO
$8.71B
| $13.7M | 4.79% |
100,000
-25,000
| -20% | -$3.28M |
|
|
12
Labcorp
LH
$25B
| $13.5M | 4.71% |
+133,860
| New | +$12.8M |
|
|
ARIA
13
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $10.2M | 3.58% |
+1,600,000
| New | +$8.97M |
|
14
AtriCure
ATRC
$1.92B
| $8.84M | 3.09% |
525,000
-175,000
| -25% | -$3.08M |
|
|
CORI
15
DELISTED
Corium International, Inc.
CORI
| $5.35M | 1.87% |
1,385,000
| – | – |
|
|
16
DexCom
DXCM
$31.5B
| $4.82M | 1.69% |
+284,000
| New | +$4.74M |
|
|
AMRN
17
Amarin Corp
AMRN
$299M
| $4.74M | 1.66% |
155,000
-120,000
| -44% | -$3.56M |
|
|
XENT
18
DELISTED
Intersect ENT, Inc
XENT
| $4.28M | 1.5% |
225,000
-24,296
| -10% | -$440K |
|
|
STRM
19
DELISTED
Streamline Health Solutions
STRM
| $1.6M | 0.56% |
75,867
| – | – |
|
20
PUT
iShares S&P 100 ETF
OEF
$20.1B
| $518K | 0.18% |
+7,000
| New | +$611K |
|
21
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| $18K | 0.01% |
1,000
-599,000
| -100% | -$117M |
|
22
AstraZeneca
AZN
$263B
| – | – |
-200,000
| Closed | -$13.6M |
|
|
23
CALL
Becton Dickinson
BDX
$45.6B
| – | – |
-51,250
| Closed | -$7.71M |
|
|
24
Becton Dickinson
BDX
$45.6B
| – | – |
-128,125
| Closed | -$19.3M |
|
25
Glaukos
GKOS
$9.83B
| – | – |
-76,502
| Closed | -$1.89M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q1 2016 Portfolio in Review
As of Q1 2016, Tamarack Advisers held 35 positions worth $286M, down 62% from $760M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Tamarack Advisers withdrew a net $416M in Q1 2016, closing 14 positions and reducing 14 holdings. Its most notable exit was Integer Holdings, an estimated $35.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 59% a quarter earlier, followed by Technology.
Against the trend, Tamarack Advisers opened a new position in Labcorp worth $13.5M.
- Tamarack Advisers's largest Q1 2016 buy was Labcorp: 133,860 shares worth $13.5M.
- Tamarack Advisers added most to Alkermes in Q1 2016, an estimated $7.31M increase.
- Tamarack Advisers's biggest Q1 2016 reduction was Patterson Companies, Inc., cutting an estimated $21.7M.
- Tamarack Advisers fully exited Integer Holdings in Q1 2016, selling an estimated $35.4M.
- Tamarack Advisers's ten largest holdings make up 76% of its $286M portfolio in Q1 2016.
- Tamarack Advisers opened 4 new positions and closed 14 in Q1 2016.
- Tamarack Advisers's portfolio value fell 62% quarter-over-quarter to $286M.
Based on Tamarack Advisers's 13F filing for Q1 2016, filed 16 May 2016.